04/07/2019 – AB Science announces the European Medicine Agency has validated the clinical development program for its new compound AB8939 in acute myeloid leukemia (AML) through a Scientific Advice procedure.
AB Science
Masitinib and AB8939 – Two compounds with breakthrough mechanism of action
